Oppenheimer analyst Matthew Biegler believes shares of Blueprint Medicines (BPMC) should rally this morning following updated results from competitor Cogent Biosciences (COGT), as disclosed in an abstract for the American Society of Hematology meeting. The firm says investors appear to be reacting to the updated safety results which showed one patient discontinuing treatment at the lowest tested dose for an alanine aminotransferase increase. Blueprint has shown no such liver toxicities in its Phase 3 PIONEER trial, the analyst tells investors in a research note. Opco believes Blueprint’s safety could end up being an “important differentiator,” given the chronic nature of treatment for indolent mastocytosis. Blueprint remains one of the firm’s top picks heading into year-end with an Outperform rating and $130 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines price target lowered to $151 from $153 at Wells Fargo
- Blueprint Medicines Reports Strong Q3 2024 Results
- Blueprint management moves maybe made with buyer in mind, says Oppenheimer
- Blueprint Medicines reports Q3 EPS (89c), consensus (96c)
- Blueprint Medicines sees FY24 global AYVAKIT net product revenues $475M-$480M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
